Fairvalue-Calculator Fairvalue-Calculator
EN DE

ProQR Therapeutics N.V (PRQR) Fair Value & Analysis

Healthcare · US · Market cap $199M

Price$1.89
Fair Value$2.39
Upside+26.5%
Quality95/100
Evidence: Low Range $1.80 – $2.99

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

ProQR Therapeutics N.V (PRQR) currently trades at $1.89, while our model-based Fair Value estimate is $2.39 — implying the stock looks roughly 26.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is ProQR Therapeutics N.V (PRQR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $2.39 versus a price of $1.89 — about +26% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PRQR?
Our 21-model fair value for ProQR Therapeutics N.V is $2.39 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.89.
What is the quality score of PRQR?
ProQR Therapeutics N.V has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.